Background/Objectives: Managing cancer-related pain presents complex challenges involving the interplay between analgesic efficacy, immune system responses, and patient outcomes. Methods: Following the Scale for the Assessment of Narrative Review Articles (SANRA) criteria, we conducted a comprehensive literature search in Medline, Scopus, and Web of Science databases. The review synthesized evidence regarding opioid pain management modalities, genetic variations affecting pain perception, and associated drug metabolism. Results: The literature reveals significant associations between opioid administration and immune function, with potential implications for cancer progression and survival. Genetic polymorphisms in key genes influence individual responses to pain opioid metabolism and, finally, pain management strategies. The immunosuppressive effects of opioids emerge as a critical consideration in cancer pain management, potentially influencing disease progression and treatment outcomes. Conclusions: Genetic variants influence analgesic efficacy, while the interaction between opioid-induced immunosuppression and genetic factors impacts both pain control and survival outcomes. This emphasizes the need for personalized treatment approaches considering individual genetic profiles and immune function.

Comparison of Fentanyl, Ketamine, and Lidocaine Combined with Propofol Anesthesia in Patients with Crohn Disease Undergoing Colonoscopy - Article abstract #944116

Colonoscopy is the gold standard for colorectal cancer screening and diagnosis of gastrointestinal disorders, yet the procedure can still provoke anxiety and pain in many patients. Advances in anesthesia and sedation techniques have significantly improved patient tolerance while maintaining procedural efficiency and safety. This review explores the physiological mechanisms of pain during colonoscopy, compares anesthetic and sedative agents—including newer drugs like remimazolam and dexmedetomidine—and evaluates emerging evidence from recent studies on sedation efficacy, safety, and patient outcomes. Special attention is given to high-risk patient populations, including those with obesity, obstructive sleep apnea, cardiovascular diseases, respiratory disorders and frailty syndrome. Propofol-based sedation remains the most commonly used agent for deep sedation. However, newer pharmacological agents with enhanced pharmacokinetic properties and improved safety profiles are increasingly influencing contemporary anesthesia practices. An individualized approach to sedation is essential. Incorporating current evidence into clinical decision-making optimizes both patient experience and procedural outcomes.